Sun Pharma, a leading Indian global pharmaceutical company, has established the Sun Professorship in Dermatology at the Icahn School of Medicine at Mount Sinai in New York.
Supported by a $2.5 million endowment from Sun Pharma, the Sun Professorship will fund academic leadership in dermatology in perpetuity, beginning with Dr. Mark G. Lebwohl as its inaugural incumbent.
Based within the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, the professorship will advance research and training, helping translate emerging knowledge into better care and prepare future leaders in the field.
As the second-largest pharmaceutical dermatology company in the U.S. by prescription volume, Sun Pharma is committed to advancing patient care through scientific innovation, education and partnerships, according to a company news release.
READ: US remains top market for Indian pharma exports in 2026 (May 7, 2026)
“At Sun Pharma, we believe meaningful progress in dermatology care requires supporting the people and institutions advancing the field today and in the future,” said Ahmad Naim, Senior Vice President and Chief Medical Officer, North America. “The establishment of this professorship reflects our long-term commitment to fostering the academic leadership needed to pursue new ideas and strengthen care for generations to come.”
Dr. Lebwohl serves as Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai and Professor and Chairman Emeritus of the Kimberly and Eric J. Waldman Department of Dermatology.
Internationally recognized for his contributions to psoriasis research and treatment, Dr. Lebwohl has helped advance understanding of inflammatory skin diseases and played a key role in shaping standards of care that have improved patient outcomes worldwide.
READ: BASF sues Apple over Face ID patent infringement, alleges unlicensed technology use (September 4, 2026)
His work as a clinician, investigator and mentor has influenced the future generation of dermatologists and helped accelerate innovation across the field. Dr. Lebwohl is Chairman Emeritus of the Medical Board of the National Psoriasis Foundation and served as President of the American Academy of Dermatology from 2015 to 2016.
“The greatest value of this professorship is the opportunity it creates to pursue important questions, support promising investigators and help turn scientific advances into better care for patients,” said Lebwohl.
Sun Pharma is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as Global Emerging Markets. Sun’s high growth Global Innovative Medicines portfolio spans innovative products in dermatology, ophthalmology, and oncodermatology and accounts for about 22% of company sales, according to the release.